Citation Impact
Citing Papers
Activation of the p62‐Keap1‐NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells
2015 Standout
miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival
2011
Global Cancer Incidence and Mortality Rates and Trends—An Update
2015 Standout
Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial
2012
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Head and neck squamous cell carcinoma
2020 Standout
Symptoms tell it all: A systematic review of the value of symptom assessment to predict survival in advanced cancer patients
2012
Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment
2013
Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis
2013
Targeted therapy of hepatocellular carcinoma: Present and future
2012
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B
2013
Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
2009
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score
2011
Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study
2009
Pathological roles of MAPK signaling pathways in human diseases
2010 Standout
Burden of liver diseases in the world
2018 Standout
Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma
2008
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Short‐ and long‐term complications of open radical prostatectomy according to the Clavien classification system
2008
Hepatitis B virus DNA levels and outcomes in chronic hepatitis B # †
2009
Hepatitis B virus subgenotyping: History, effects of recombination, misclassifications, and corrections
2013
Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis
2007
Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis
2015
Hepatocellular carcinoma
2012 Standout
Prognosis prediction and staging
2014
Hepatitis B virus infection
2009 Standout
Hepatocellular carcinoma
2021 Standout
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
Surveillance for Hepatocellular Carcinoma Improves Survival in Asian-American Patients with Hepatitis B: Results from a Community-Based Clinic
2009
Hepatitis B virus X protein induces hypermethylation of p16INK4Apromoter via DNA methyltransferases in the early stage of HBV-associated hepatocarcinogenesis
2009
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
Disease Burden of Hepatocellular Carcinoma: A Global Perspective
2019
Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?
2015
Cancer-associated cachexia
2018 Standout
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
2019
Preoperative Prognostic Score for Predicting Survival After Hepatic Resection for Colorectal Liver Metastases
2007
Thermal ablation of tumours: biological mechanisms and advances in therapy
2014 Standout
Global cancer statistics
2011 Standout
Long-Term Results of Two-Stage Hepatectomy for Irresectable Colorectal Cancer Liver Metastases
2008
Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma
2010
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Hepatitis B reactivation after chemotherapy: two decades of clinical research
2008
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018
Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis
2015
Chronic hepatitis B
2007 Standout
Chronic hepatitis B: Update 2009 #
2009 Standout
Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review. CME
2006
Role of viral factors in the natural course and therapy of chronic hepatitis B
2007
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
2012 Standout
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
Global burden of liver disease: 2023 update
2023 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
Hepatocellular Carcinoma
2011
Treatment of intermediate-stage hepatocellular carcinoma
2014
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis
2018
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)
2008
Health-Related Quality of Life in Patients With Hepatocellular Carcinoma: A Systematic Review
2010
Macrophage M1/M2 polarization
2020 Standout
Molecular therapies and precision medicine for hepatocellular carcinoma
2018
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA
2015 StandoutNobel
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort
2011
Medical treatments for hepatocellular carcinoma (HCC): what’s next?
2006
Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma
2010
Hepatocellular Carcinoma
2011 Standout
Renal cell carcinoma
2017 Standout
Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants
2017
The Clavien-Dindo Classification of Surgical Complications
2009 Standout
Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents
2008
Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials
2009
Hepatocellular carcinoma
2022 Standout
The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma
2012
Older Female Cancer Patients: Importance, Causes, and Consequences of Undertreatment
2007
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
2006
Hepatocellular Carcinoma
2019 Standout
AASLD guidelines for the treatment of hepatocellular carcinoma
2017 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers
2010
High CYP2E1 activity aggravates hepatofibrosis by limiting macrophage polarization towards the M2 phenotype
2019
Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma
2019
Lyso-Thermosensitive Liposomal Doxorubicin: An Adjuvant to Increase The Cure Rate of Radiofrequency Ablation in Liver Cancer
2011
Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005
2009 Standout
Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
2006
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
2020
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
2006
Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
2008
Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nolatrexed or Doxorubicin
2007
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
2013 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations
2014
Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma
2008
Comparison of hepatocellular carcinoma in E astern versus W estern populations
2016
Global cancer statistics, 2012
2015 Standout
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
2013
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
2009 Standout
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
2015 Standout
Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma
2015
Works of Jane Koh being referenced
A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma
2005
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma
2006
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
2008
Liver Resection after Irinotecan, 5-Fluorouracil, and Folinic Acid for Patients with Unresectable Colorectal Liver Metastases: A Multicenter Phase II Study by the Cancer Therapeutic Research Group
2005
Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data
2017
Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response
2015
Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy
2007
An Intensive Surveillance Program Detected a High Incidence of Hepatocellular Carcinoma Among Hepatitis B Virus Carriers With Abnormal Alpha-Fetoprotein Levels or Abdominal Ultrasonography Results
2005
False-Negative Rate of Abdominal Sonography for Detecting Hepatocellular Carcinoma in Patients with Hepatitis B and Elevated Serum α-Fetoprotein Levels
2004
A phase III study of doxorubicin (A) versus cisplatin (P)/ interferonα-2b (I)/ doxorubicin (A)/ fluorouracil (F) combination chemotherapy (PIAF) for inoperable hepatocellular carcinoma (HCC)
2004
High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma
2008
A phase III study of doxorubicin (A) versus cisplatin (P)/ interferonα-2b (I)/ doxorubicin (A)/ fluorouracil (F) combination chemotherapy (PIAF) for inoperable hepatocellular carcinoma (HCC)
2004
Applicability of BALAD score in prognostication of hepatitis B ‐related hepatocellular carcinoma
2015
An intensive screening program detected high incidence of hepatocellular carcinoma (HCC) in hepatitis B virus carriers (HBVC) with abnormal alfa-fetoprotein (AFP) or abdominal ultrasongraphy (AUS)
2004